<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Atherosclerotic <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> is a major cause of <z:hpo ids='HP_0011420'>death</z:hpo> for uremic patients who are on hemodialysis (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Recent evidence suggests that <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> (a) [Lp(a)] may aggravate <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> by inhibiting activation of transforming growth factor-beta 1 (TGF-beta 1) </plain></SENT>
<SENT sid="2" pm="."><plain>Plasma Lp(a) and plasma TGF-beta 1 activation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> patients (n = 51), <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> patients not subjected to hemodialysis (non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CRF; n = 12), and healthy volunteers (control; n = 13) were investigated </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma Lp(a) was significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> (18.75 +/- 1.62 mg/ml) and non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CRF patients (25.0 +/- 8.4 mg/ml) than in control subjects (10.9 +/- 5.8 mg/ml) </plain></SENT>
<SENT sid="4" pm="."><plain>The degree of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> patients was assessed by measuring the intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) and plaque score with the use of an ultrasound scanner </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> and plaque score were higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> and non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CRF patients than in controls </plain></SENT>
<SENT sid="6" pm="."><plain>A significant positive correlation was found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> patients between Lp(a) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> (r = 0 </plain></SENT>
<SENT sid="7" pm="."><plain>377, P &lt; 0.01) as well as between Lp(a) and plaque score (r = 0.43, P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma total TGF-beta 1 significantly increased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> (119.8 +/- 53.5 ng/ml) and non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-CRF patients (93.2 +/- 25.0 ng/ml) compared with control subjects (17.7 +/- 6.4 ng/ml), whereas the plasma level of mature (active) TGF-beta1 did not differ among the groups </plain></SENT>
<SENT sid="9" pm="."><plain>When plasma TGF-beta 1 and supernatant TGF-beta 1 from cultured peripheral mononuclear cells were compared before and after an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> session, neither total nor mature TGF-beta 1 showed a significant difference between the values before and after an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> session </plain></SENT>
<SENT sid="10" pm="."><plain>There were no significant relationships between plasma total TGF-beta 1 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> or plaque score, between mature TGF-beta 1 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> or plaque score, or between mature TGF-beta 1 and Lp(a) </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, Lp(a) may be an important atherogenic factor in CRF patients </plain></SENT>
<SENT sid="12" pm="."><plain>However, it was not clarified whether Lp(a) exerts its effect by inhibiting TGF-beta 1 activation in CRF patients </plain></SENT>
</text></document>